The Neuropathology Core is an essential part of the Alzheimer's Disease Core Center (ADCC). During life, the signs and symptoms of Alzheimer's disease (AD) are not sufficiently different from several other conditions, resulting in misdiagnosis, even at the most advanced centers, in about 25% of subjects. Examination of the brain after death by a certified Neuropathologist is therefore the only means by which a definite diagnosis can be attained, allowing all research results to be correctly interpreted. A second major role of the Neuropathology Core is to provide neuropathologically characterized brain tissue to basic scientists, both within the ADCC and outside it, enabling them to discover the underlying molecular mechanisms of disease and design appropriate therapeutic interventions. A detailed understanding of the genetic and molecular processes of disease pathogenesis, obtained by comparative study of diseased and non-diseased brain tissue, remains the major approach to finding such interventions. A third important goal of the Neuropathology Core is to help develop a collaborative synergy that will enhance the research productivity of the entire Center.
Our Specific Aims are as follows: 1)To provide precise neuropathoiogic diagnoses of patients that have been clinically studied by the Cinical Core. 2) To provide basic scientists with neuropathologically characterized brain tissue suitable for the elucidation of the molecular mechanisms of AD and related disorders, and especially to assist researchers in their studies of the earliest stages of Alzheimer's disease, with the goal of identifying therapeutic strategies that will prevent the disease or slow its progress. 3) To share neuropathological skills, expertise, knowledge and data with all ADCC investigators and the scientific community at large, facilitating a collaborative synergy that will enhance the research productivity of all.

Public Health Relevance

The Arizona Alzheimer's Disease Center's Neuropathology Core provides autopsy services, brain measurements and diagnoses, and brain and body samples from research participants in the Clinical Core who have died and donated their brains (and sometimes their bodies) to advance the scientific understanding, treatment and prevention of Alzheimer's disease. It works closely with the other Cores and plays a critical role in the scientific fight against Alzheimer's Disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG019610-15
Application #
8805818
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Banner Health
Department
Type
DUNS #
City
Phoenix
State
AZ
Country
United States
Zip Code
85351
Wu, Jianfeng; Zhang, Jie; Shi, Jie et al. (2018) HIPPOCAMPUS MORPHOMETRY STUDY ON PATHOLOGY-CONFIRMED ALZHEIMER'S DISEASE PATIENTS WITH SURFACE MULTIVARIATE MORPHOMETRY STATISTICS. Proc IEEE Int Symp Biomed Imaging 2018:1555-1559
Cabrera, Erwin; Mathews, Paul; Mezhericher, Emiliya et al. (2018) A? truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochim Biophys Acta Mol Basis Dis 1864:208-225
Tariot, Pierre N; Lopera, Francisco; Langbaum, Jessica B et al. (2018) The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's diseas Alzheimers Dement (N Y) 4:150-160
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Beach, Thomas G; Serrano, Geidy E; Kremer, Thomas et al. (2018) Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4). J Neuropathol Exp Neurol 77:793-802
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Weise, Christopher M; Chen, Kewei; Chen, Yinghua et al. (2018) Left lateralized cerebral glucose metabolism declines in amyloid-? positive persons with mild cognitive impairment. Neuroimage Clin 20:286-296
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Ren, Yingxue; van Blitterswijk, Marka; Allen, Mariet et al. (2018) TMEM106B haplotypes have distinct gene expression patterns in aged brain. Mol Neurodegener 13:35
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827

Showing the most recent 10 out of 794 publications